Table 1.
Hemagglutination inhibition (HI) and IgG-anti-HA, nucleoprotein (NP), M2e titers in mice groups prior to virus challenge.
| Gr. No. | Immunogen | Denotation used in study | Anti-HA IgG antibody titer (GM ± SE) | Anti-NP IgG antibody titer (GM ± SE) | Anti-M2e IgG antibody titer (GM ± SE) | HI titer (GM ± SE) |
|---|---|---|---|---|---|---|
| Formulations administered as two doses | ||||||
| 1 | 10 µg HA + Mw | Mw-HA | 20,318 ± 4,267 | – | – | 64 ± 13 |
| 2 | 10 µg NP + Mw | Mw-NP | – | 58,813 ± 10,240 | – | – |
| 3 | 10 µg HA + 10 µg NP + Mw | Mw-HN | 6,400 ± 0 | 102,400 ± 25,083 | – | 32 ± 6.7 |
| 4 | 10 µg HA + 10 μg NP + 50 μg M2e + Mw | Mw-HNM | 4,031 ± 1,067 | 270,235 ± 50,165 | 126 ± 33 | 4.3 ± 6 |
| 5 | 10 µg HA | OP-HA | 5,080 ± 1,067 | – | – | 20 ± 0 |
| 6 | 10 µg NP | OP-NP | – | 102,400 ± 0 | – | – |
| 7 | 10 µg HA + 10 μg NP | OP-HN | 2,540 ± 1,600 | 51,200 ± 17,363 | – | 25 ± 6.7 |
| 8 | 10 µg HA + 10 μg NP + 50 μg M2e | OP-HNM | 2,540 ± 533 | 22,286 ± 7,011 | 504 ± 133 | 4.3 ± 6 |
| Formulations administered as a single dose | ||||||
| 9 | 10 µg HA + 10 µg NP + 50 µg M2e + Mw | Mw-HNM | 504 ± 133 | 155,209 ± 79,977 | 317 ± 67 | – |
| 10 | 10 µg HA + 10 μg NP + 50 μg M2e | OP-HNM | 1,600 ± 0 | 102,400 ± 155,402 | 252 ± 67 | – |
| 11 | 50 µg HA + 50 μg NP + 50 μg M2e + Mw | 50-Mw-HNM | 1,270 ± 267 | 3,200 ± 0 | 79 ± 17 | – |